--- title: "How Investors May Respond To Thermo Fisher Scientific (TMO) Deepening Its Role In Late‑Stage mRNA Manufacturing" type: "News" locale: "en" url: "https://longbridge.com/en/news/291728732.md" description: "Thermo Fisher Scientific (TMO) deepened its role in late-stage mRNA manufacturing through a collaboration with Arcturus Therapeutics for the ARCT-032 cystic fibrosis therapy. This partnership reinforces TMO's end-to-end capabilities in complex biologics, aligning with its investment narrative as a diversified provider to pharma and biotech sectors. While expanding its development-to-commercialization toolkit, key near-term catalysts remain lab spending trends and China exposure risks." datetime: "2026-07-05T20:01:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/291728732.md) - [en](https://longbridge.com/en/news/291728732.md) - [zh-HK](https://longbridge.com/zh-HK/news/291728732.md) --- # How Investors May Respond To Thermo Fisher Scientific (TMO) Deepening Its Role In Late‑Stage mRNA Manufacturing - In late June and early July 2026, Arcturus Therapeutics announced a collaboration with Thermo Fisher Scientific, under which Thermo Fisher will supply integrated Phase 3 manufacturing, clinical research and potential commercial manufacturing services for ARCT-032, an investigational mRNA therapy for cystic fibrosis. - This agreement aligns Thermo Fisher even more closely with cutting-edge mRNA and rare disease workflows, expanding its role as an end-to-end development and manufacturing partner in complex biologics. - Next, we'll examine how Thermo Fisher’s deepening role in late-stage mRNA manufacturing through ARCT-032 could influence its investment narrative. Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. ## Thermo Fisher Scientific Investment Narrative Recap To own Thermo Fisher, you generally need to believe in its role as a diversified picks-and-shovels provider to pharma, biotech and diagnostics, with resilient demand for its tools, consumables and services even when individual end markets are choppy. The Arcturus ARCT-032 collaboration reinforces Thermo Fisher’s end-to-end presence in complex biologics, but it does not materially change the near term focus on lab spending trends and China exposure as key catalysts and risks. Among recent announcements, the AustinPx KinetiSol agreement is especially relevant, because it broadens Thermo Fisher’s advanced oral drug manufacturing toolkit in a way that echoes the ARCT-032 mRNA deal: both deepen its role as a development-to-commercialization partner. Together, these moves sit alongside upcoming Q2 2026 earnings as important reference points for how well Thermo Fisher is converting its expanded capabilities into growth while managing margin and funding headwinds. Yet while these partnerships look promising, investors should also be aware that persistent weakness in China and tariff-related margin pressure could... Read the full narrative on Thermo Fisher Scientific (it's free!) Thermo Fisher Scientific's narrative projects $54.1 billion revenue and $9.5 billion earnings by 2029. This requires 6.2% yearly revenue growth and about a $2.7 billion earnings increase from $6.8 billion today. Uncover how Thermo Fisher Scientific's forecasts yield a $611.56 fair value, a 17% upside to its current price. ## Exploring Other Perspectives TMO 1-Year Stock Price Chart Compared with consensus, the most optimistic analysts already expected Thermo Fisher to reach about US$56.0 billion in revenue and US$10.2 billion in earnings by 2029, so this new ARCT-032 partnership could either support that upbeat view or highlight how sensitive those forecasts are to trade and China risks if conditions shift. Explore 6 other fair value estimates on Thermo Fisher Scientific - why the stock might be worth 6% less than the current price! ## Reach Your Own Conclusion Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts. - A great starting point for your Thermo Fisher Scientific research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. - Our free Thermo Fisher Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Thermo Fisher Scientific's overall financial health at a glance. ## Interested In Other Possibilities? The market won't wait. These fast-moving stocks are hot now. Grab the list before they run: - Uncover the next big thing with 20 elite penny stocks that balance risk and reward. - Find 44 companies with promising cash flow potential yet trading below their fair value. - Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### Valuation is complex, but we're here to simplify it. Discover if Thermo Fisher Scientific might be undervalued or overvalued with our detailed analysis, featuring **fair value estimates, potential risks, dividends, insider trades, and its financial condition.** Access Free Analysis ### Related Stocks - [TMO.US](https://longbridge.com/en/quote/TMO.US.md) - [ARCT.US](https://longbridge.com/en/quote/ARCT.US.md) ## Related News & Research - [Thermo Fisher Scientific Inc. $TMO Shares Sold by Dynamic Advisor Solutions LLC](https://longbridge.com/en/news/295318083.md) - [Balefire LLC Sells 2,144 Shares of Thermo Fisher Scientific Inc. $TMO](https://longbridge.com/en/news/295069344.md) - [Eldred Rock Partners LLC Has $15.25 Million Stake in Thermo Fisher Scientific Inc. $TMO](https://longbridge.com/en/news/295295371.md) - [Top Thermo Fisher Executive Makes Major Move With High-Value Stock Sale](https://longbridge.com/en/news/295293054.md) - [CX Institutional Has $9.82 Million Position in Thermo Fisher Scientific Inc. $TMO](https://longbridge.com/en/news/294789171.md)